TickerFacts.

Company research / BBOT

BridgeBio Oncology Therapeutics, Inc. (BBOT)

Build a valuation ↗↓ Download CSV

CIK 0001869105 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

Key ratios (year ended 2025-12-31)

-32.6%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-05

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Period ended2025-12-312024-12-312023-12-31
R&D Expense$121.20M$73.11Mn/a
Operating Income-$145.82M-$80.86M-$41.7K
Net Income-$134.04M-$74.28M-$41.7K
EPS (Diluted)-$4.30-$5756.41n/a
Total Assets$448.38M$164.30M$332.9K
Total Liabilities$37.28M$19.58M$396.5K
Shareholders' Equity$411.10M-$178.64M-$63.6K
Cash & Equivalents$373.69M$30.85Mn/a
Operating Cash Flow-$113.89M-$55.03Mn/a
Capital Expenditures$606.0K$49.0Kn/a
Free Cash Flow-$114.50M-$55.08Mn/a
Shares Outstanding79.99M28.4Kn/a
Weighted Average Diluted Shares31.14M12.9Kn/a
EPS (Basic)-$4.30-$5756.41n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView